Browsing the blog archives for October, 2007.

Tamoxifen Prevents Breast Cancer in High-Risk Women, Study Confirms

Breast cancer du sein, Research news recherche

The initial findings from the Italian trial showed no significant reduction in breast cancer risk with tamoxifen use. However, the National Surgical Adjuvant Breast and Bowel Project’s Breast Cancer Prevention Trial found that tamoxifen reduced the risk of estrogen receptor-positive breast cancer.

Umberto Veronesi, M.D., of the European Institute of Oncology in Milan, and colleagues randomly assigned 5,408 healthy women who had a hysterectomy to receive tamoxifen or a placebo for five years.

After 11 years of follow-up, 136 women developed breast cancer–74 in the placebo group and 62 in the tamoxifen group. Among low-risk women, rates of breast cancer were similar in the tamoxifen and placebo groups. But for women at high risk, breast cancer rates were lower for those taking tamoxifen. Women taking tamoxifen experienced more side effects, including hot flashes and heart problems, than women in the placebo group.

“A complete assessment of the baseline cardiovascular risk should become an important component of counseling women on the use of tamoxifen, particularly in the prevention setting,” the authors write.

Reference: Journal of the National Cancer Institute 

No Comments

Accuracy Of Breast Cancer Prognoses Improved

Research news recherche

ScienceDaily (Oct. 17, 2007) — One of the many unknowns facing women who are diagnosed with breast cancer is predicting the likelihood that the cancer will spread to other parts of the body — metastasize. Researchers from UC San Diego are looking to change that. UCSD bioengineering professor Trey Ideker is pioneering a more accurate approach for predicting the risk of breast cancer metastasis in individual patients.

Distant metastases are the main cause of death among breast cancer patients, but physicians have a hard time predicting if a patient’s breast cancer is likely to spread.

The researchers from UCSD and the Korea Advanced Institute of Science and Technology took advantage of new protein interaction databases and identified networks of genes from breast cancer patients — rather than individual genes — that can be used to predict whether a breast cancer tumor is likely to spread.

Their results offer new mechanistic insights into breast cancer metastasis and are more accurate and reproducible than two sets of individual marker genes currently used to help predict the likelihood that a patient’s breast cancer will spread.

“Over the years, large numbers of women have endured unnecessarily harsh treatments, such as aggressive chemotherapy, due to our inability to predict metastasis risks with high accuracy. One of our goals is to improve this situation,” said Trey Ideker, a bioengineering professor from the UCSD Jacobs School of Engineering and the senior author of the new study.

“The next step is to confirm these results in other clinical trials. It will be absolutely crucial to confirm our findings on other patient data before we think too hard about bringing this technology to the clinic,” Ideker said.

The new research may also help researchers discover disease-causing genes and more precisely classify and diagnose cancer and other diseases.

“Our work supports the notion that cancer is a disease of pathways,” said Ideker. “The keys for understanding at least some of these pathways are encoded in protein networks.”

The new study uses the same gene expression data used in two well-known studies: Vijver et al. in Nature and Wang et al. in the Lancet. Each study yielded a set of about 70 single-gene markers that are now used in hospitals to help predict the likelihood of breast cancer metastasis.

“We saw about a 9 percent increase in metastasis prediction accuracy over the two main sets of individual gene markers,” said Ideker, who explained that his team raised metastatic prediction accuracy for breast cancer to roughly 72 percent. “But there is still plenty of room for improvement,” he said.

“The big difference between our work and the work outlined in Vijver and Wang is that we painted the existing gene expression data onto newly available maps of protein interactions,” said Ideker. Some refer to these maps as “wiring diagrams.”

By focusing on how the proteins within cells interact, the researchers were able to look at the aggregate behavior of genes that are connected in functional networks. This approach improved their ability to predict which tumors would spread.

Using a mathematical approach for the prediction of metastasis (involving both machine learning and dimensionality reduction), the researchers calculated the average behavior of subnetworks of proteins and used this information to uncover subnetworks that predict metastasis better than individual gene markers.

The team uncovered 149 discriminative subnetworks consisting of 618 genes from the patients from the van de Vijver et al. data set and 243 discriminative subnetworks with 906 genes from the Wang et al. data set.

Each subnetwork is suggestive of a distinct functional pathway or complex, yielding many known and novel pathway hypotheses in organisms for which sufficient protein interaction data have been measured, the authors write in their Molecular Systems Biology paper.

For example, the researchers show that a well-known breast cancer susceptibility gene, P53, plays a central role in several protein subnetworks; it interconnects many expression-responsive genes (genes that show up as potential markers in expression-only analyses). Interestingly, P53 itself does not show up as “significant” in conventional expression clustering or classification methods.

“A key feature of our approach is the ability to identify crucial genes that fly under the radar of conventional gene expression analyses,” said Ideker.

The phenotypic changes most indicative of breast cancer metastasis need not be regulated at the level of expression, the authors write.

The researchers also show that their subnetwork markers are significantly more reproducible between data sets than individual marker genes selected without network information.

This work will be published online by the journal Molecular Systems Biology on Tuesday 16 October.

The team’s members hail from the Department of Bioengineering at the UCSD Jacobs School, the UCSD Bioinformatics Program, the UCSD Moores Cancer Center, and the Korea Advanced Institute of Science and Technology.

Network-based classification of breast cancer metastasis, Han-Yu Chuang1,5, Eunjung Lee2,3,5, Yu-Tsueng Liu4, Doheon Lee3 and Trey Ideker1,2,4*

  1. Bioinformatics Program, University of California San Diego, La Jolla, California 92093
  2. Department of Bioengineering, University of California San Diego, La Jolla, California
  3. Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology, Daejeon 305-701, Korea
  4. Moores Cancer Center, University of California San Diego, La Jolla, California
  5. These authors contributed equally to this work.
No Comments

Cancer study shows racial, cultural divide

Research news recherche

by Chris Clackum, NBC News
ANCHORAGE, Alaska — A new report from the National Institutes of Health offers mixed news about cancer survival rates.

More people are beating the disease, according to the study, except for Native Americans and Alaska Natives.

Dr. Edward Benz, Jr., with the Dana Farber Cancer Institute said researchers have found increased rates in those groups for both lung and colorectal cancer.

“We still have major differences among different groups of people there are still disparities in how well patients are going,” Benz said.

Dr. Benz cited limited access to health care as possible reasons for the discrepancy.

He said prevention and early detection are keys to helping boost survival rates not just in minority groups, but for everyone.

No Comments

D’excellentes chances de guérison pour l’épouse de Calvillo

Lymph cancer

Le Dr Ahmed Galal, qui supervise les traitements subis par la femme d’Anthony Calvillo à l’hôpital Royal Victoria, a beaucoup rassuré le vétéran quart arrière des Alouettes, hier. «Les chances de guérison sont excellentes, affirme le Dr Galal. Il y a même 60% de chances de guérison après un premier traitement en chimiothérapie et en radiothérapie, et le traitement initial a été administré il y a quelques heures à peine.»

Le Dr Galal est très familier avec ce type de cancer des ganglions. «Le lymphome malin à cellules B n’est pas considéré comme un cancer très agressif, expliquet- il. Il se traite bien avec les soins appropriés. Si les traitements en chimiothérapie et en radiothérapie ne produisaient pas les effets voulus, nous devrions alors procéder à une greffe de cellules souches.»

Sans les traitements appropriés, l’état de santé de la conjointe de Calvillo pourrait se détériorer très rapidement.

«Lorsque le lymphome malin à cellules B n’est pas maîtrisé, les ganglions, les poumons et le coeur peuvent être attaqués assez rapidement, explique le Dr Galal. C’est crucial de traiter ce cancer dans les plus brefs délais possibles.»

Calvillo reconnaissant

Par le biais d’un communiqué, Anthony Calvillo a remercié ses coéquipiers et les fans des Alouettes qui le soutiennent dans cette épreuve.

«Nous tenons à remercier tous ceux qui nous ont fait parvenir leurs voeux et prières, a mentionné Calvillo. Nous sommes confiants d’obtenir une guérison complète, mais le fait demeure que le soutien des gens dans une telle situation est vraiment apprécié.»

No Comments
« Older Posts


Free web hosting Web hosting